MindBio Therapeutics Corp. (the Company or MindBio), reported its major discovery from sleep data obtained from randomized controlled trials LSD-Microdosing from 3231 nights of sleep in 80 clinical trial participants. MindBio reported preliminary findings from sleep data obtained from 3231 nights of sleep, recording, measuring and analysing the sleep patterns of participants in the LSD-Microdosing treatment group n=40 against the placebo group n=40.

The Company announced it has made a major discovery confirmatory of positive sleep responses to MindBio's LSD-Microdosing treatment. Not only does LSD-Microdosing improve subjective feelings of mood and feelings of happiness, energy, creativity, social connectivity and wellness, it also has a statistically significant impact on quality of sleep. The ground-breaking findings are important, particularly in depression, and some related mental health conditions where MindBio has a scientific interest, such as pre-menstral dysmorphic disorder, where quality of sleep is disproportionately compromised and seen as a significant contributor to down-spiralling mental health.

A common first line of treatment to mood and sleep disruption is the use of anti-depressants plus sleeping pills. Sleeping pills pose a potential reliance, misuse and addiction risk and the negative unacceptable side effects from anti-depressants (such as weight gain, agitation, gastro-intestinal upset and sexual impotence) are well reported.1 The positive sleep data from MindBio's proprietary LSD-Microdosing treatment is ground-breaking in respect of potentially replacing existing treatments for mood and sleep disruption that are often ineffective and have unacceptable side effects. MindBio's discovery adds to the Company's Big Data strategy, adding to its intellectual property to effectively treat patients with mental health disorders through MindBio's proprietary LSD-Microdosing treatment program.

Phase 2 LSD-Microdosing trials to begin shortly. MindBio has two fully funded Phase 2 LSD-Microdosing clinical trials starting shortly. The first trial focuses on Major Depressive Disorder, where 20 patients meeting DSM-V criteria will receive an open label 8-week LSD microdosing treatment regimen in a naturalistic at-home setting.

This trial will serve as the basis for continuing a much larger Phase 2b triple-dummy, active placebo-controlled trial in depressed patients. The second trial explores the effectiveness of LSD-Microdosing in conjunction with Meaning Centred Psychotherapy in late-stage cancer patients experiencing emotional distress. This randomized, double-blind, and placebo-controlled trial will involve 40 participants and is set to begin recruiting participants for the trial shortly.